Abstract
Hepatocellular carcinoma (HCC) is a frequent neoplasia which still misses a therapeutical gold standard. Recently, new acquisitions in cancerogenesis process evidenced the genetic and epigenetic alterations of genes involved in the different metabolic pathways of liver cancer suggesting that antibodies, small molecules, demethylating agents, etc. specifically acting against molecular target can be utilized alone or in combination in clinical practice. The main altered targets are: cell membrane receptors, in particular tyrosine kinase receptors, factors involved in cell signalling, specifically Wnt/β-catenin, Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways, proteins linked to cell cycle regulation pathway (i.e. p53, p16/INK4, cyclin/cdk complex) or in invasiveness (EMT, TGFbeta) and proteins involved in DNA metabolism. Genetic or epigenetic changes in these molecules have been used in preclinical settings and, some of them also in clinical trials of phase II and III. This scenario opens new avenues for the prevention and the treatment of HCC. In the present review the main metabolic pathways and molecular alterations have been described together with recent advances in molecular and gene therapy.
Keywords: Hepatocarcinoma, target therapies, molecular alterations, cellular pathways
Current Pharmaceutical Design
Title: Molecular Pathways and Related Target Therapies in Liver Carcinoma
Volume: 13 Issue: 32
Author(s): S. Tommasi, R. Pinto, B. Pilato and A. Paradiso
Affiliation:
Keywords: Hepatocarcinoma, target therapies, molecular alterations, cellular pathways
Abstract: Hepatocellular carcinoma (HCC) is a frequent neoplasia which still misses a therapeutical gold standard. Recently, new acquisitions in cancerogenesis process evidenced the genetic and epigenetic alterations of genes involved in the different metabolic pathways of liver cancer suggesting that antibodies, small molecules, demethylating agents, etc. specifically acting against molecular target can be utilized alone or in combination in clinical practice. The main altered targets are: cell membrane receptors, in particular tyrosine kinase receptors, factors involved in cell signalling, specifically Wnt/β-catenin, Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways, proteins linked to cell cycle regulation pathway (i.e. p53, p16/INK4, cyclin/cdk complex) or in invasiveness (EMT, TGFbeta) and proteins involved in DNA metabolism. Genetic or epigenetic changes in these molecules have been used in preclinical settings and, some of them also in clinical trials of phase II and III. This scenario opens new avenues for the prevention and the treatment of HCC. In the present review the main metabolic pathways and molecular alterations have been described together with recent advances in molecular and gene therapy.
Export Options
About this article
Cite this article as:
Tommasi S., Pinto R., Pilato B. and Paradiso A., Molecular Pathways and Related Target Therapies in Liver Carcinoma, Current Pharmaceutical Design 2007; 13 (32) . https://dx.doi.org/10.2174/138161207782360663
DOI https://dx.doi.org/10.2174/138161207782360663 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
Endocrine, Metabolic & Immune Disorders - Drug Targets Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Lemongrass (<i>Cymbopogon citratus</i> (D.C.) Stapf) Presents Antitumoral Effect and Improves Chemotherapy Activity in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Products as Anticancer Agents
Current Drug Targets PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Synthesis of Novel Amides Based on Acridone Scaffold with Interesting Antineoplastic Activity
Anti-Cancer Agents in Medicinal Chemistry Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Synthesis, In Vitro Biological Screening and Molecular Docking Studies of Novel Camphor-Based Thiazoles
Medicinal Chemistry Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Fermentation of Beet Juice Using Lactic Acid Bacteria and its Cytotoxic Activity Against Human Liver Cancer Cell Lines HepG2
Current Bioactive Compounds Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Relationship Between Body Mass Index and Reproduction
Current Women`s Health Reviews Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Developments Towards a Prophylactic Hepatitis C Virus Vaccine
Current Immunology Reviews (Discontinued)